Two cases of eczematous eruptions caused by everolimus
Abstract Objective Everolimus, an inhibitor of the mammalian target of rapamycin, has been used in the treatment of several types of tumor. Erythematous maculopapular and acneiform rashes are the major dermatological adverse events associated with everolimus therapy, but we encountered two cases of...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-10-01
|
| Series: | Journal of Cutaneous Immunology and Allergy |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cia2.12075 |
| Summary: | Abstract Objective Everolimus, an inhibitor of the mammalian target of rapamycin, has been used in the treatment of several types of tumor. Erythematous maculopapular and acneiform rashes are the major dermatological adverse events associated with everolimus therapy, but we encountered two cases of eczematous eruption caused by everolimus. Method We assessed the clinical features and laboratory findings of the two cases. Results A 52‐year‐old woman and a 59‐year‐old man developed pruritic papules and erythema over their entire bodies after initiation of everolimus therapy. Both patients exhibited peripheral eosinophilia and increased serum thymus and activation‐regulated chemokine (TARC) levels. A skin biopsy from one patient revealed the features of chronic dermatitis. Both the skin manifestations and the pruritis disappeared rapidly after the discontinuation of everolimus treatment. The peripheral blood eosinophil and serum TARC levels also decreased. Conclusion Eczematous eruption associated with an elevated serum TARC level is a dermatological event associated with everolimus therapy. |
|---|---|
| ISSN: | 2574-4593 |